<DOC>
	<DOCNO>NCT03063437</DOCNO>
	<brief_summary>The objective study provide preliminary insight safety efficacy fecal microbiota transplantation ( FMT ) eradication gastrointestinal carriage vancomycin-resistant Enterococcus .</brief_summary>
	<brief_title>A Trial Encapsulated Fecal Microbiota Vancomycin Resistant Enterococcus Decolonization</brief_title>
	<detailed_description />
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Adults 18 year old time enrollment . Able provide sign date informed consent . Identified VREpositive stool culture within last 7 day . Women childbearing potential sexual relationship men must use acceptable method contraceptionÂ§ 30 day prior enrollment 4 week complete study treatment . Males must agree avoid impregnation woman four week complete study treatment . Includes , limit , barrier additional spermicidal foam jelly , intrauterine device , hormonal contraception ( start least 30 day prior study enrollment ) , intercourse men underwent vasectomy . Female patient pregnant , lactate plan become pregnant study . Female patient childbearing potential undergo pregnancy test , exclude study positive . Inability ( e.g . dysphagia ) unwilling swallow capsule . Active ARB gastrointestinal infection time enrollment . Patient receive antibiotic last 48 hour . Patients eligible enroll antibiotic therapy discontinue minimum 48 hour prior randomization . Requires continue antibiotic use anticipate antibiotic use upcoming 4 week . Known suspect toxic megacolon and/or know small bowel ileus . Major gastrointestinal surgery ( e.g . significant bowel resection ) within 3 month enrollment . This include appendectomy cholecystectomy . History total colectomy bariatric surgery . Admitted expect intensive care unit medical reason ( board ) . Patients reside nursing home , longterm care facility rehabilitation center may enrol . Concurrent intensive induction chemotherapy , radiation therapy biological treatment active malignancy . Patients maintenance chemotherapy may enrol consultation medical monitor . Unable unwilling comply protocol requirement . Expected life expectancy &lt; 6 month Previous FMT microbiomebased product time exclude study . Patients history severe anaphylactic anaphylactoid food allergy . Solid organ transplant recipient 90 day posttransplant active treatment rejection . Neutropenia ( 500 neutrophils/mL ) severe immunosuppression . AntiTNF permit . Patients monoclonal antibody B T cell . glucocorticoid , antimetabolite ( azathioprine , 6mercaptopurine , methotrexate ) , calcineurin inhibitor ( tacrolimus , cyclosporine ) mycophenolate mofetil may enrol consultation medical monitor . If risk CMV/EBV associate disease ( investigator 's discretion , e.g . immunocompromised ) , negative IgG test cytomegalovirus ( CMV ) Epstein Barr Virus ( EBV ) . A condition would jeopardize safety right subject , would make unlikely subject complete study , would confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>vancomycin resistant enterococcus</keyword>
	<keyword>VRE</keyword>
	<keyword>decolonization</keyword>
	<keyword>VRE colonization</keyword>
	<keyword>fecal microbiota transplantation</keyword>
	<keyword>FMT</keyword>
	<keyword>FMT capsule</keyword>
	<keyword>capsule</keyword>
	<keyword>antimicrobial resistance</keyword>
	<keyword>antibiotic resistance</keyword>
	<keyword>MDRO</keyword>
	<keyword>multidrug-resistant organism</keyword>
	<keyword>OpenBiome</keyword>
</DOC>